Abstracts tagged "Biologic agents"

Abstract Number: 2589 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Treatment Profile of Patients with Psoriatic Arthritis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Mei Liu², Sabrina Rebello³, Meghan Glynn², Peter Hur⁴ and Philip J. Mease⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Few real-world studies have characterized patients with psoriatic arthritis (PsA) who initiate secukinumab. This study described characteristics of patients who initiated secukinumab and other…
Abstract Number: 553 • 2018 ACR/ARHP Annual Meeting
Channeling to Treatment and Associated Changes in Disease Activity Over 12 Months in Patients With RA Treated With Abatacept Versus Other DMARDs in Real-World Community Practice Settings
Leticia Ferri¹, Jeffrey R. Curtis², Ying Bao¹, Evo Alemao¹, Tammy Curtice¹, Joshua Bryson¹, Karissa Lozenski¹, Sandhya Balachandar¹ and Varshini Rajagopalan³, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Alabama at Birmingham, Birmingham, AL, ³Mu Sigma, Bangalore, India
Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulatory modulator, has shown efficacy similar to TNF inhibitors (TNFi) for RA management in clinical trial settings, but different…
Abstract Number: 1592 • 2018 ACR/ARHP Annual Meeting
Frequency and Pattern of the Uveitis in Spondyloarthritis with Biological Therapy
Itziar Calvo Zorrilla¹, Edurne Guerrero Basterretxea¹, Oihane Ibarguengoitia¹, David Montero¹, Maria Luz Garcia Vivar¹, Esther Ruíz Lucea², Ignacio Torre Salaberri², Olaia Begoña Fernandez Berrizbeitia², Juan Maria Blanco Madrigal², Ana Rosa Inchaurbe Pellejero¹, Clara Eugenia Perez Velasquez², Natalia Rivera-García³, Maria Jesus Allande Lopez Linares³, Iñigo Gorostiza-Hormaetxe⁴ and Eva Galíndez Agirregoikoa², ¹Rheumatology, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ³Rheumatology, University Hospital of Basurto, Bilbao, Spain, ⁴Research Department, Basurto University Hospital, Bilbao, Spain
Background/Purpose: Uveitis is the most frequent extra-articular manifestation (EAM) of spondyloarthritis (SpA). Its prevalence is approximately 30% and increases with the duration of the SpA. The…
Abstract Number: 2597 • 2018 ACR/ARHP Annual Meeting
The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Patient Reported Outcomes in Axial Spondyloarthritis; A Systematic Literature Review and a Call for Action
Santiago Rodrigues Manica^1,2, Joana Leite Silva³, Ana Rita Machado⁴, Constança Coelho⁵, Joana Duarte⁶, Elsa Vieira-Sousa⁷, José Tavares Costa⁸ and Fernando Pimentel-Santos^1,2, ¹CEDOC, NOVA Medical School, Lisbon, Portugal, ²Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ³Serviço de Reumatologia da Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁴Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ⁵Genetics Laboratory, Institute of Environmental Health, Lisbon School of Medicine, University of Lisbon, Lisbon, Portugal, ⁶Medical Department, Novartis Pharma, Pharmaceutical products, Oeiras, Portugal, ⁷Rheumatology Department, CAML, Lisbon, Portugal, Lisbon, Portugal, ⁸Rheumatology Department, ULSAM, Ponte de Lima, Portugal, Ponte de Lima, Portugal
Background/Purpose: Patient reported outcomes (PROs) have gained relevance in the evaluation of axial SpA (axSpA), as they convey a more objective patient perspective. The concept…
Abstract Number: 554 • 2018 ACR/ARHP Annual Meeting
Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?
Yuki Ishikawa¹, Motomu Hashimoto², Hiromu Ito³, Masao Tanaka², Naoichiro Yukawa⁴, Takao Fujii⁵, Wataru Yamamoto⁶, Tsuneyo Mimori⁷ and Chikashi Terao^8,9,10, ¹One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ²Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Wakayama University, Wakayama, Japan, ⁵Dept of Rheum/Clinical Immun, Wakayama Medical University, Wakayama, Japan, ⁶Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁸Center for Investigative Medical Sciences, RIKEN, Yokohama, Japan, ⁹Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, ¹⁰Department of Applied Genetics, The School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
Background/Purpose: It has been well known that anti-TNF-α treatment for RA patients is associated with ANA development. We previously reported that ANA development along with…
Abstract Number: 1593 • 2018 ACR/ARHP Annual Meeting
Extra-Articular Manifestations, Neoplasms and Cardiovascular Events in a Series of Spondyloarthritis from a Single Center
Itziar Calvo Zorrilla¹, Edurne Guerrero Basterretxea¹, Oihane Ibarguengoitia¹, David Montero¹, Maria Luz Garcia Vivar¹, Esther Ruíz Lucea², Ignacio Torre Salaberri², Olaia Begoña Fernandez Berrizbeitia², Juan Maria Blanco Madrigal², Ana Rosa Inchaurbe Pellejero¹, Clara Eugenia Perez Velasquez², Natalia Rivera-García³, Maria Jesus Allande Lopez Linares³, Iñigo Gorostiza-Hormaetxe⁴ and Eva Galíndez Agirregoikoa², ¹Rheumatology, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ³Rheumatology, University Hospital of Basurto, Bilbao, Spain, ⁴Research Department, Basurto University Hospital, Bilbao, Spain
Background/Purpose: Spondyloarthritis(SpA) is characterized by axial, peripheral and extra-articular manifestation(EAMs). Its frequency depends on the series, being the psoriasis(Ps), uveitis and inflammatory bowel disease(IBD) the…
Abstract Number: 2611 • 2018 ACR/ARHP Annual Meeting
Multidrug Resistant AxSpA: No Advantage of Switching Class in Patients with Inadequate Response to Two Prior TNFi Agents
Sevket Ercan Tunc¹, Ismail Sari¹, Robert D Inman² and Nigil Haroon², ¹Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada
Background/Purpose: Lack of efficacy (LOE) to TNF inhibitor (TNFi) treatments is an important issue and can be seen in up to 40% of the patients…
Abstract Number: 573 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis
Pascal Hilliquin¹, Thomas Barnetche², Guy Baudens³, Ralph Niarra⁴, Isabelle Idier⁵ and Alain Saraux⁶, ¹Rheumatology, Hôpital Sud Francilien, Corbeil-Essonne, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHR Valenciennes, Valenciennes, France, ⁴Biostatistics, Keyrus of behalf of Roche SAS, Boulogne-Billancourt, France, ⁵Medical department, Chugai Pharma France, Paris La Defense, France, ⁶Rheumatology, CHU Brest, Brest, France
Background/Purpose: In France, tocilizumab (TCZ) subcutaneous (sc) 1st prescription and yearly renewal are restricted to hospital. Monitoring may be done by both office-based or hospital…
Abstract Number: 1615 • 2018 ACR/ARHP Annual Meeting
Comparative Risk of Atrial Fibrillation and Cardiovascular Events between TNF-Inhibitors and Ustekinumab in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Moa Lee¹, Rishi J. Desai², Yinzhu Jin³, Gregory Brill¹, Alexis Ogdie⁴ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease is a major comorbidity in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Increasing evidence suggests a potential reduction in the risk…
Abstract Number: 2624 • 2018 ACR/ARHP Annual Meeting
Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis
Dongze Wu¹, Tingting Xu², Isaac T. Cheng¹, Steven H.M. Lam¹, Jiang Yue¹, Priscilla Wong¹, Edmund Li¹, Tena K. Li¹ and Lai-Shan Tam³, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²China Center for Health Development Studies, Peking University, Beijing, China; Department of Health Policy and Administration, Peking University School of Public Health, Beijing, China, Beijing, China, ³Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong
Background/Purpose: For patients with psoriatic arthritis (PsA) failing the first TNF-inhibitor, switching to biologic DMARDs [bDMARDs] with different mechanism of actions (swapping strategy) may be…
Abstract Number: 577 • 2018 ACR/ARHP Annual Meeting
Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis
Ted R. Mikuls¹, Amrita Bath², Bryant R. England³, Michael J. Duryee⁴, Carlos D. Hunter⁴, Joel Kremer⁵, Dimitrios A. Pappas^6,7, William H. Robinson⁸, Jeffrey R. Curtis⁹ and Geoffrey M. Thiele¹⁰, ¹Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Albany Medical Center, Albany, NY, ⁶Columbia University, New York, NY, ⁷Corrona, LLC, Waltham, MA, ⁸Stanford University, Palo Alto, CA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Although biologics represent a major advance in rheumatoid arthritis (RA), many patients fail to achieve adequate responses to these agents. As previous studies have…
Abstract Number: 1655 • 2018 ACR/ARHP Annual Meeting
Achieving Remission in Psoriatic Arthritis By Early Initiation of TNF Inhibition: A Double-Blind, Randomized, Placebo-Controlled Trial of Golimumab + Methotrexate Versus Placebo + Methotrexate
Leonieke van Mens¹, Jet de Jong², Inka Fluri¹, Marleen van de Sande³, Michael Nurmohamed⁴, M.R. Kok⁵, Arno van Kuijk⁶ and Dominique Baeten², ¹Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ⁵Rheumatology, Maasstad Ziekenhuis, Rotterdam, Netherlands, ⁶Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands
Background/Purpose: In inflammatory arthritis such as RA, early initiation of highly effective targeted treatments is a successful strategy to aim for sustained remission.1 Here we…
Abstract Number: 2676 • 2018 ACR/ARHP Annual Meeting
SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment
Ioannis Parodis^1,2, Sharzad Emamikia^1,2, Alvaro Gomez¹ and Katerina Chatzidionysiou^2,3, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In systemic lupus erythematosus (SLE), organ damage is associated with unfavourable disease courses and premature mortality. We aimed at investigating the impact of organ…
Abstract Number: 590 • 2018 ACR/ARHP Annual Meeting
Advances in Therapeutic Management with First Biological Therapy in Rheumatoid Arthritis throughout 15 Years
Patricia Bogas¹, Chamaida Plasencia², Victoria Navarro-Compán³, Diego Benavent², Gabriela Gonzalez², María Gema Bonilla Hernán², Irene Monjo¹ and Juan Molina¹, ¹Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain
Background/Purpose: In the last two decades the treatment in patients with rheumatoid arthritis (RA) has undergone major advances, especially due to the appearance of new…
Abstract Number: 1704 • 2018 ACR/ARHP Annual Meeting
Clinical SLE Disease Activity Index Score of Zero May be a More Pragmatic Outcome Measure in SLE Studies
Ioannis Parodis^1,2, Sharzad Emamikia^1,2, Iva Gunnarsson^1,2, Ronald F. van Vollenhoven^2,3 and Katerina Chatzidionysiou^1,4, ¹Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ³Amsterdam Rheumatology and Immunology Center ARC, Department of Clinical Immunology & Rheumatology, University of Amsterdam, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Drug development in systemic lupus erythematosus (SLE) has been challenging. One of the reasons can be traced in the choice of outcome measures. In…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].